A synthetic lethality-based strategy to treat cancers harboring a genetic deficiency in the chromatin remodeling factor BRG1.
Oike T, Ogiwara H, Tominaga Y, Ito K, Ando O, Tsuta K, Mizukami T, Shimada Y, Isomura H, Komachi M, Furuta K, Watanabe S, Nakano T, Yokota J, Kohno T.
Oike T, et al. Among authors: nakano t.
Cancer Res. 2013 Sep 1;73(17):5508-18. doi: 10.1158/0008-5472.CAN-12-4593. Epub 2013 Jul 19.
Cancer Res. 2013.
PMID: 23872584